With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.75416-51-2,8-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,75416-51-2
8-Bromo-1,2,3,4-tetrahydroisoquinoline 14.1 (200 mg, 0.804 mmol) was suspended in tetrahydrofuran (4 ml) and saturated sodium bicarbonate (2 ml) then di-t-butyl dicarbonate (263 mg, 1.21 mmol) was added as a solution in THF (2 ml) and the mixture was stirred atRT for 42 h. The reaction mixture was poured into water and extracted three times with ethyl acetate. The organic extract was dried over sodium sulfate, filtered and evaporated. The residue was purified via flash silica chromatography (heptane I DCM 0-80percent) to provide compound 14.2 (200 mg, 80percent) as a colourless oil. 1H NMR (ODd3, 400 MHz) O 1.30 (5, 9H), 2.82 (m, 2H), 3.63 (m, 2H), 4.60 (m, 2H), 7.05 (m, 2H), 7.39 (d, 1H). UPLC-MS (shortbasic) rt 1.01 (255, 257 [M-tBu+H]), 96percent pure.
As the paragraph descriping shows that 75416-51-2 is playing an increasingly important role.
Reference£º
Patent; THE UNIVERSITY OF SHEFFIELD; RICHARDS, Gareth; SKERRY, Timothy, M.; HARRITY, Joseph, P.A.; ZIRIMWABAGABO, Jean-Olivier; TOZER, Matthew, J.; GIBSON, Karl, Richard; PORTER, Roderick, Alan; BLANEY, Paul, Matthew; GLOSSOP, Paul, Alan; (369 pag.)WO2018/211275; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem